Aclarion Inc. (ACON)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $9.32 per share a year ago.
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
“Matching the right procedure to the right patient is what moves the field forward” BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights
$AERA $BCBC $ACON $SKYX $AUUD $SSII $BIEI $ATCH PRISM MarketViev About PRISM MediaWire PRISM MediaWire is a New York City–based press release distribution company specializing in capital markets communications for publicly traded companies.
Aclarion Announces $2.5 Million Stock Repurchase Plan
Highlights Disciplined Capital Allocation While Supporting Continued Nociscan® Adoption Broomfield, CO, April 22, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Broomfield, CO, April 16, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S.
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
BROOMFIELD, Colo., March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 Broomfield, CO, March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Broomfield, CO, March 17, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)– Aclarion, Inc.
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Broomfield, CO, February 5, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Appoints Greg Gould as Chief Financial Officer
HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
